ArticleThyroid research2025
Low risk of thyroid eye disease (TED) following radioiodine (RAI) therapy in a multidisciplinary setting: a retrospective cohort study.
Article in Thyroid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on: 'Thyroid eye disease and steroid therapy: risk stratification for bone health'.Eye (London, England) · 2026Article
- The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadioiodine (RAI) is recommended by the National Institute of Clinical Excellence (NICE) as a first-line definitive treatment of Grave’s hyperthyroidism (GH). RAI is cited as a major risk factor in the development and exacerbation of thyroid eye disease (TED). We aim to identify the current risk of TED in a population treated post 2015.
methodsThis is a retrospective cohort study including all adult patients diagnosed with GH undergoing RAI over a seven-year period. Data collected included age; gender; thyroid diagnosis and pre- and post-treatment thyroid status; length of GH; TSHR-Ab titres; smoking status; RAI dose and number of treatments; ophthalmology assessment and use of steroid prophylaxis. Investigation results, clinical scoring and management details were collected from patients who developed TED following RAI.
resultsFour of 231 patients (1.7%) treated with RAI over 8 years had new onset (two patients) or progression (two patients) of TED following their RAI. One required immunosuppression and one rehabilitative TED surgery. No patient developed sight-threatening TED.
conclusionsIn our study, judicious screening for high-risk patients and the use of prophylactic steroids results in lower rates of RAI associated TED relative to those reported previously in the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.